微小病变性肾病与局灶节段性肾小球硬化的分子生物学研究进展

Research Progress of Molecular Biology in Minimal Change Disease and Focal Segmental Glomerulosclerosis

微小病变肾病(MCD)和局灶节段性肾小球硬化(FSGS)为儿童期原发性肾病综合征(NS)的2种最常见病理学类型。目前仍采用肾穿刺活检术对MCD及FSGS进行鉴别诊断。研究表明,许多生物因子在MCD及FSGS的发生及发展中起着重要作用,并存在成为MCD或FSGS生物标志物的潜力。本文聚焦膜抗原CD80、脂质过氧化物、骨桥蛋白(OPN)、血管内皮生长因子受体(VEGFR)-2、半乳糖凝集素(galectin)、胰岛素样生长因子结合蛋白(IGFBP)、转化生长因子(TGF)-β1、微小核糖核酸(miRNA)及成纤维细胞特异蛋白(FSP)-1等生物因子在MCD和FSGS鉴别诊断中的研究进展,旨在提升临床对这2种原发性NS病理学类型的发病机制及诊疗的认识。

Minimal change disease（MCD）and focal segmental glomerulosclerosis（FSGS）are the two most common types of primary nephrotic syndrome（NS）in children.Until now,we differentiate these two types through renal biopsy.According to some literatures,many biological factors play roles in pathogenesis and development of MCD and FSGS.These biological factors have the potential to become biomaker for MCD or FSGS.This paper focuses on the research progress of CD80,malondialdehyde,osteopontin,vascular endothelial growth factor（VEGFR）-2,galectins,insulin-like growth factor binding protein（IGFBP）-β1,transforming growth factor（TGF）,microRNA（miRNA）,fibroblast-specific protein（FSP）-1 in differential diagnosis of MCD and FSGS.In order to enhance the awareness of pathogenesis,diagnosis and treatment of these two pathological types of primary NS.